Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Multicenter Study to Assess Response to Influenza Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously

Next Previous
X
Search
Trial Profile

An Open-label Multicenter Study to Assess Response to Influenza Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Ofatumumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 02 Mar 2024 Results assessing whether patients with RMS treated with OMB 20 mg every 4 weeks can mount an HIR inactivated influenza vaccine compared with patients treated with interferon or glatiramer acetate presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024
    • 03 Oct 2023 Status changed from recruiting to completed.
    • 05 Dec 2022 Planned End Date changed from 6 Jul 2022 to 6 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top